-
Why do people with Crohn's disease develop chronic pancreatitis? Case study
Time of Update: 2023-02-03
After considering the patient's clinical presentation, laboratory findings, and history, we concluded that in the past 6 months, due to intestinal fistula and duodenal obstruction, fecal fluid has flowed retrograde into the descending duodenal segment and pancreatic duct, resulting in a recurrence of acute pancreatitis.
-
Clinical efficacy of alvartrombopag compared with recombinant human thrombopoietin in the treatment of severe thrombocytopenia associated with chronic liver disease: a real-world clinical study
Time of Update: 2022-11-01
The first medical video of "Xinsu" invited Professor Wang Jizhou, Department of Hepatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China, to explain the clinical study of chronic liver disease (CLD)-related severe thrombocytopenia (TCP) recently published in Frontiers in Pharmacology.
-
【PHILIPS case per day】MRI illusion realistic: suspected subdural hematoma
Time of Update: 2022-10-31
In this case, the initial MRI resembles an atypical subdural hematoma, in which case we should consider a pathologic biopsy as soon as possible rather than follow-up.
-
Does fatigue in patients with fatty liver have an impact on clinical outcomes? Research Express
Time of Update: 2022-10-21
The results showed that fatigue was mainly caused by depression, sleep disturbance and cardiovascular disease (CVD) in patients with NAFLD, and was associated with an increased risk of death.
-
Express $1.1 billion capsule received Phase 2/3 clinical therapy, Novo Nordisk expands the blood disease pipeline
Time of Update: 2022-09-06
Resources:[1] Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.
▎ WuXi AppTec content team editor▲ Etavopivat molecular structural formula (Image source: PubChem)Resources:[1] Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.
-
Complete remission of metastatic gastric cancer, how did he do
Time of Update: 2022-08-20
, Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery, Front Immunol.
, Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery, Front Immunol.
-
NEUROLOGY: White matter hyperintensity volume correlates with cognition 1 year after stroke
Time of Update: 2022-05-24
White matter hyperintensity (WMH) , a key feature of SVD , has been shown to decrease or increase in stroke, cognitively impaired individuals, older community dwellers surveyed for neurological or cognitive symptoms, and healthy adults ( mean age 63 years ) .
-
The good news of domestic new crown drug research continues, what is the next step
Time of Update: 2022-05-20
How to develop new crown drugs in the post-epidemic era The current mainstream methods for treating mild to moderate symptoms of new coronary pneumonia include vaccines, neutralizing antibodies, small molecule drugs, and traditional Chinese medicine .
-
Express treatment of chronic hepatitis B, Tengsheng Bo Yao announced the latest clinical results of RNAi therapy phase 2
Time of Update: 2022-04-27
Professor Jia Jidong, Liver Disease Research Center, Beijing Friendship Hospital, Capital Medical University, said: "In this study, after two doses of BRII-835 (VIR-2218), serum HBsAg levels in HBeAg-negative and HBeAg-positive Chinese patients with chronic HBV infection were dose-dependent.
-
Diabetes Care: Circulating palmitoyl sphingomyelin is associated with cardiovascular disease in patients with type 2 diabetes
Time of Update: 2022-04-17
In the discovery cohort, untargeted metabolomic analysis identified 16 lipid and fatty acid metabolites associated with CVD risk in patients with diabetes, with palmitoyl sphingomyelin (PSM) having the strongest association .
-
Want to know your "life span
Time of Update: 2022-02-18
In the current analysis, DunedinPACE accelerated in middle-aged and older adults with increased risk of chronic disease, disability, and mortality; across the lifespan, DunedinPACE correlated with biological age measures from blood chemistry and DNA methylation data and studies Participants' subjective perceptions of their own health .
-
DTP pharmacy is becoming the key layout direction of pharmaceutical retail enterprises
Time of Update: 2022-01-10
For example, by adapting to market changes, adjusting organizations, and increasing the proportion of prescription drugs, ordinary people have led the development and introduction of new specialty drugs, chronic disease and severe medications, hospital clinical drugs, and new specialty drugs (DTP specialty pharmacies) stores across the country.
-
The "first" new drug approved globally in 2021
Time of Update: 2022-01-09
Rybrevant (Amivantamab-vmjw), an EGFR-MET bispecific antibody with immune cell targeting activity, was approved by the FDA in May for the treatment of disease progression after failure of platinum-containing chemotherapy and positive EGFR gene exon 20 insertion mutation ( Adult patients with metastatic non-small cell lung cancer (mNSCLC) with EGFRex20ins+ have become the world's first targeted therapy approved for the treatment of EGFRex20ins+ NSCLC .
-
IBD: A genetic variant in patients with Crohn's disease is closely related to disease recurrence after surgery
Time of Update: 2021-12-03
immunity This study confirmed that the new gene mutation site rs2060886 in TCF4 is associated with a genome-wide significant level of surgical recurrence risk in CD patients after the first abdominal surgery .
-
Bring 91% of patients back to normal triglycerides and innovative oligonucleotide therapy advances to phase 3 clinical trials
Time of Update: 2021-11-14
On November 2, 2021, Ionis Pharmaceuticals announced the initiation of a pivotal Phase 3 clinical trial of the antisense oligonucleotide (ASO) therapy olezarsen under development.
Reference materials:[1] Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia.
